Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
173.53-1.27 (-0.73%)
At close: 4:00 PM EDT

173.53 0.00 (0.00%)
After hours: 4:43 PM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close174.80
Bid172.75 x 500
Ask173.75 x 5000
Day's Range172.83 - 174.42
52wk Range130.09 - 176.85
1y Target EstN/A
Market Cap129.86B
P/E Ratio (ttm)17.76
Avg Vol (3m)2,864,382
Dividend & Yield4.00 (2.29%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 hours ago

    Amgen Opens Nomination Process For LabCentral Residency

    CAMBRIDGE, Mass., Sept. 26, 2016 /PRNewswire/ -- Amgen (AMGN) today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life-sciences and biotech startup companies in Massachusetts. LabCentral is an innovative, shared laboratory space designed as a launch pad for premier high-impact life-sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two early-stage companies each year to take up residence in LabCentral's Kendall Square facilities in Cambridge, Mass.

  • TheStreet.com3 hours ago

    Wall Street Sells Off on Worries Over Clinton-Trump Showdown

    Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.

  • PR Newswire3 hours ago

    Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab

    THOUSAND OAKS, Calif. and BRUSSELS, Sept. 26, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. "We believe romosozumab could serve as an important therapeutic option for osteoporosis patients with an increased risk of fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. The BLA, submitted on July 19, 2016, is based on data from the pivotal Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME) in approximately 7,200 patients.